Navidea Announces Second Quarter 2014 Financial Results; Total Revenues Grow to $1.1 Million Aug 6, 2014
Navidea Biopharmaceuticals to Announce Second Quarter 2014 Financial Results on August 6, 2014 Jul 29, 2014
Navidea Joins Essex Woodland’s Rheumco to Develop Radiopharmaceuticals for Detection and Treatment of Arthritic Diseases Jul 16, 2014
Navidea to Webcast Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers July 8, 2014 Jul 2, 2014
Navidea Biopharmaceuticals to Present at the 9th Annual JMP Securities Healthcare Conference Jun 17, 2014
U.S. FDA Approves Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection for Expanded Use in Head and Neck Cancer Sentinel Lymph Node Biopsy Jun 13, 2014
Navidea Biopharmaceuticals’ Lymphoseek® (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis Jun 11, 2014
Navidea Biopharmaceuticals Announces Positive Lymphoseek® (technetium Tc 99m tilmanocept) Injection Results on Injection Timing and Surgery Across Multiple Solid Tumor Types Jun 10, 2014
Navidea Announces Data Demonstrating Potential of Manocept™ Platform to Diagnose Rheumatoid Arthritis and Kaposi’s Sarcoma Jun 10, 2014
